Halofenate (MK-185) was invented as a hypolipidemic and hypouricemic agent. It was shown that halofenate lower serum triglycerides and uric acid in patients with a variety of hyperlipidemias. Treatment of dyslipidemic type 2 diabetic patients also showed triglyceride lowering and, surprisingly, significant reductions in plasma glucose and insulin. Halofenate is a selective PPAR-γ modulator (SPPARγM). SPPARγMs are believed to bind in distinct manners to the ligand-binding pocket of PPAR-γ, leading to altered receptor conformational stability and resulting in distinct patterns of gene expression. Thus, was suggested that halofenate hold promising therapeutic potential in the treatment of type 2 diabetes, without the side effects. However, information about the current use of this compound is not available.

Cimoxatone is a fully reversible inhibitor selective for the A form of monoamine oxidase. Oral administration of Cimoxatone increased brain noradrenaline, dopamine, and serotonin and decreased DOPAC , 5-HIAA, and 3-methoxy-4-hydroxyphenylethylene glycol sulfate.

Brocresine, an aromatic L-amino acid decarboxylase inhibitor with both a peripheral and central action was shown to potentiate the therapeutic effect of levodopa in Parkinson's disease.

Triflumidate is a fluoroalkanesulfonanilide. It had been identified for clinical trials. This non-steroidal compound is an anti-inflammatory agent.

Dinsed is a coccidiostat used in poultry to stop the growth of coccidian parasites.

Guinea green B is an organosulfur stain. It is used as a dye for silk and wool fabrics and as a biological stain.